Showing results (61-70 of 132) with videos related to

Sort By:
Pageof 14
Diagnostic Microbiology and Infectious Disease|March 16, 2005
Reproducibility of gemifloxacin and comparison fluoroquinolone MIC results using Sensititre commercial dry-form panelsJames E Ross, Helio S Sader, Thomas R Fritsche, et al.
Antimicrobial Agents and Chemotherapy|January 9, 2008
Antimicrobial activity of omiganan pentahydrochloride against contemporary fungal pathogens responsible for catheter-associated infectionsThomas R Fritsche, Paul R Rhomberg, Helio S Sader, et al.
International Journal of Antimicrobial Agents|November 23, 2006
Occurrence of plasmidic AmpC type beta-lactamase-mediated resistance in Escherichia coli: report from the SENTRY Antimicrobial Surveillance Program (North America, 2004)Lalitagauri M Deshpande, Ronald N Jones, Thomas R Fritsche, et al.
International Journal of Antimicrobial Agents|January 24, 2007
Oxazolidinone susceptibility patterns for 2005: International Report from the Zyvox Annual Appraisal of Potency and Spectrum StudyJames E Ross, Thomas R Fritsche, Helio S Sader, et al.
Antimicrobial Agents and Chemotherapy|June 28, 2006
Activity of retapamulin (SB-275833), a novel pleuromutilin, against selected resistant gram-positive cocciRonald N Jones, Thomas R Fritsche, Helio S Sader, et al.
The Journal of Antimicrobial Chemotherapy|December 6, 2005
Oxazolidinone susceptibility patterns in 2004: report from the Zyvox Annual Appraisal of Potency and Spectrum (ZAAPS) Program assessing isolates from 16 nationsRonald N Jones, James E Ross, Thomas R Fritsche, et al.
Diagnostic Microbiology and Infectious Disease|April 6, 2007
Garenoxacin activity against isolates form patients hospitalized with community-acquired pneumonia and multidrug-resistant Streptococcus pneumoniaeRonald N Jones, Helio S Sader, Matthew G Stilwell, et al.
Microbial Drug Resistance (Larchmont, N.Y.)|January 18, 2007
Occurrence and characterization of carbapenemase-producing Enterobacteriaceae: report from the SENTRY Antimicrobial Surveillance Program (2000-2004)Lalitagauri M Deshpande, Ronald N Jones, Thomas R Fritsche, et al.
Diagnostic Microbiology and Infectious Disease|November 13, 2007
Selection of a surrogate beta-lactam testing agent for initial susceptibility testing of doripenem, a new carbapenemRonald N Jones, Helio S Sader, Thomas R Fritsche, et al.
Diagnostic Microbiology and Infectious Disease|March 24, 2009
Antimicrobial activity of doripenem tested against prevalent Gram-positive pathogens: results from a global surveillance study (2003-2007)Thomas R Fritsche, Helio S Sader, Matthew G Stillwell, et al.
Pageof 14